ADEOYE Y OLUKOTUN
CIK 1242615 · Chief Medical Officer · last filed 2026-05-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.88M
Companies
6
Total Filings
48
Lifetime Open-Market Net
-$1.70M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TNXP | Director | 0 | $11.65 | $0 | $5.0K | 11 | 2026-05-14 |
| ARWR | Director | 33,600 | $85.83 | $2.88M | -$1.71M | 12 | 2025-12-23 |
| BIOCLINICA INC (BIOC) Delisted | Director | 0 | $0.43 | $0 | $0 | 3 | 2013-03-14 |
| ICAGEN INC (ICGN) Delisted | Director | 0 | — | — | $0 | 11 | 2011-10-28 |
| BIOCLINICA INC (UWBK) Delisted | Director | — | — | — | $0 | 3 | 2010-05-13 |
| VIA Pharmaceuticals, Inc. (VIAP) Delisted | Chief Medical Officer | 59,624 | — | — | $0 | 3 | 2007-12-19 |
Recent Filings · Page 2 of 5
48 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-20 | ARWR | Grant (A) | +16,733 | $384.7K | EDGAR |
| 2024-05-24 | TNXP | Grant (A) | — | $0 | EDGAR |
| 2023-12-19 | ARWR | Grant (A) | +14,987 | $380.8K | EDGAR |
| 2023-05-10 | TNXP | Grant (A) | — | $0 | EDGAR |
| 2023-03-06 | ARWR | Sell (S) | −11,350 | -$370.6K | EDGAR |
| 2023-01-11 | ARWR | Grant (A) | +7,867 | $0 | EDGAR |
| 2022-05-11 | TNXP | Grant (A) | — | $0 | EDGAR |
| 2022-01-07 | ARWR | Grant (A) | +6,400 | $0 | EDGAR |
| 2022-01-04 | ARWR | Sell (S) | −4,050 | -$262.2K | EDGAR |
| 2021-09-14 | ARWR | Sell (S) | −5,000 | -$318.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.